Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development

This article was originally published in PharmAsia News

Executive Summary

BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development

You may also be interested in...



China FDA Set To Greenlight First Domestic Lymphoma Drug

On the verge of obtaining its first new drug approval from the China FDA to treat a rare cancer type, Chinese domestic biotech ChipScreen is poised to benefit from an increasingly confident regulatory agency.

Reverse Innovation In China: An Interview With HUYA CEO Mireille Gillings

Eight years ago, HUYA’s CEO Mireille Gillings began screening compounds developed in China to bring them to global markets. Nowadays, the company says it has a database with more than 12,000 compounds and 2,000 biomarkers from China.

Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference

BEIJING - With China's government poised to invest substantial funds in coming years to encourage innovative drug development, China is quickly becoming a favorite R&D destination for multinational pharmas, but both public and private players are still grappling with how to boost R&D productivity

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel